GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
R-lipoic is both a water and fat soluble antioxidant, therefore is able to work anywhere in the body.Studies suggest that Lipoic acid assists with nerve health, and has been indicated to benefit those with diabetes and nerve disorders
Acting on the enteric nervous system, it influences gastrointestinal motility and visceral sensitivity
Most patients experience complete recovery, though some may have residual nerve dysfunction, emphasizing the importance of timely intervention
These scaling efforts aimed to address immediate food insecurity while contributing to broader food system transitions and/or the enhancement of local development
Healthy habits extend results
